ALBATROSS Study: International Multicenter Study for Prospective

Status Recruiting

Clinical Trial Summary

This Clinical study is framed in the ALBATROSS Project: Clinically validated decision support system based on pixel level Artificial Intelligent models for deciding treatment in glioblastoma. The prospective multicenter international dataset compiled during the ALBATROSS project will include a cohort up to 300 new patients diagnosed with GB after June 1, 2020. Longitudinal images (T1, T2, T1c, FLAIR, PWI-DSC and DWI at least), complete molecular profiling, primary and secondary lines of treatment and clinical conditions will be included for each patient.

Clinical Trial Description

The Hypothesis under study in this project is: Therapeutic decision making during clinical management of patients with glioblastoma may benefit from delineating functional habitats at pixel level relative to growth, proliferation, infiltration and angiogenesis The Overall Scientific Objectives of the research proposal are to: OSO1. Delineate functional habitats from multiparametric MRI relative to the growth, proliferation, infiltration and angiogenesis at the enhanced tumor and infiltrated peripheral edema OSO2. Demonstrate that functional habitats at enhanced tumors and infiltrated peripheral edema show structural, cellular and molecular differences related to the heterogeneity of the tumor region and are compatible with mathematical models of glioma growth and infiltration OSO3. Determine the in-vivo molecular sub-type of patients with glioblastoma from image biomarkers in functional habitats OSO4. Identify groups of patients with glioblastoma presenting positive therapeutic response in terms of longer survival using image biomarkers from functional habitats OSO5. Position ONCOhabitats as a clinical decision support system for the management of patients with glioblastoma ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05229198
Study type	Observational
Source	Universitat Politècnica de València
Contact	María del Mar Álvarez-Torres, Ms
Phone	669933613
Email	maaltor4@upv.es
Status	Recruiting
Phase
Start date	June 1, 2020
Completion date	June 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02766699` - A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM)	Phase 1
Not yet recruiting	`NCT06017063` - Coaching for Coping in Glioblastoma Patients and Caregivers and Its Association With Compliance to TTFields	N/A
Completed	`NCT02366728` - DC Migration Study for Newly-Diagnosed GBM	Phase 2
Terminated	`NCT04489420` - Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM	Phase 1
Withdrawn	`NCT02432417` - The Addition of Chloroquine to Chemoradiation for Glioblastoma,	Phase 2
Completed	`NCT04757662` - Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma	Phase 1
Withdrawn	`NCT05218408` - CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type	Phase 1/Phase 2
Recruiting	`NCT05375318` - BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and Histopathological Levels
Not yet recruiting	`NCT06161974` - Study of Olutasidenib and Temozolomide in HGG	Phase 2
Withdrawn	`NCT00943462` - Study of 18F-FEC for Positron Emission Tomography-Computed Tomography (PET-CT) Imaging of GBM
Completed	`NCT02709226` - Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma	Phase 1
Completed	`NCT01240460` - Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection	Phase 1
Recruiting	`NCT06118723` - The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Recruiting	`NCT06157541` - T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma	Phase 1/Phase 2
Terminated	`NCT02510950` - Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma	Phase 1
Withdrawn	`NCT03956706` - Study of Stereotactic Radiosurgery to the Subventricular Zone in Malignant Gliomas	N/A
Completed	`NCT02465268` - Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme	Phase 2
Completed	`NCT03072134` - Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma	Phase 1
Recruiting	`NCT03861299` - The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients.	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

ALBATROSS Study: International Multicenter Study for Prospective Validation of Imaging Biomarkers Calculated at Vascular Habitats of High-grade Gliomas — ALBATROSS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms